SGC3027 is a prodrug of SGC8158, which is a novel, selective and potent inhibitor of protein arginine N-methyltransferase (PRMT7) with anticancer activity.
Physicochemical Properties
| Molecular Formula | C41H47CLN6O6S |
| Molecular Weight | 787.37 |
| Exact Mass | 786.296 |
| CAS # | 2624313-13-7 |
| PubChem CID | 137333447 |
| Appearance | Light yellow to yellow solid powder |
| LogP | 5.7 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 14 |
| Heavy Atom Count | 55 |
| Complexity | 1470 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | [C@H]1([C@H](O)[C@@H](CSCCCCN(CC2=CC(C3C=CC(Cl)=CC=3)=CC=C2)C(CC(C)(C)C2C(=O)C(C)=C(C)C(C=2C)=O)=O)O[C@H]1N1C=NC2C(N)=NC=NC=21)O |
| InChi Key | MLJVGAYSVYMPSB-MSUKGTQXSA-N |
| InChi Code | InChI=1S/C41H47ClN6O6S/c1-23-24(2)35(51)32(25(3)34(23)50)41(4,5)18-31(49)47(19-26-9-8-10-28(17-26)27-11-13-29(42)14-12-27)15-6-7-16-55-20-30-36(52)37(53)40(54-30)48-22-46-33-38(43)44-21-45-39(33)48/h8-14,17,21-22,30,36-37,40,52-53H,6-7,15-16,18-20H2,1-5H3,(H2,43,44,45)/t30-,36-,37-,40-/m1/s1 |
| Chemical Name | N-[4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methylsulfanyl]butyl]-N-[[3-(4-chlorophenyl)phenyl]methyl]-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)butanamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | The prodrug of SGC8158, SGC3027, releases the active component after being lowered in cells by reductase. SGC3027 reduced HSP70 methylation in cell studies using C2C12 cells, with an IC50 value of 1.3 μM[2]. |
| References |
[1]. Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation. Molecules. 2018 Aug 6;23(8). pii: E1958. [2]. SGC3027 for PRMT7. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~317.51 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (2.64 mM) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2701 mL | 6.3503 mL | 12.7005 mL | |
| 5 mM | 0.2540 mL | 1.2701 mL | 2.5401 mL | |
| 10 mM | 0.1270 mL | 0.6350 mL | 1.2701 mL |